These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6168845)

  • 1. N"-Cyano-N-4-pyridyl-N'-1,2,2-trimethyl-propylguanidine, a new vasodilating agent: acute effect of blood pressure and pharmacokinetics in hypertensive patients.
    Kardel T; Hilden T; Carlsen J; Trap-Jensen J
    J Cardiovasc Pharmacol; 1981; 3(5):1002-7. PubMed ID: 6168845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pinacidil, a new vasodilator: pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension.
    Carlsen JE; Kardel T; Jensen HA; Tangø M; Trap-Jensen J
    Eur J Clin Pharmacol; 1983; 25(4):557-61. PubMed ID: 6653652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous pinacidil in the acute treatment of hypertension.
    Rijk MC; Thien T
    J Clin Pharmacol; 1987 Jul; 27(7):468-74. PubMed ID: 3308975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immediate central and peripheral haemodynamic effects of a new vasodilating agent Pinacidil (P1134) in hypertensive man.
    Carlsen JE; Kardel T; Hilden T; Tangø M; Trap-Jensen J
    Clin Physiol; 1981 Aug; 1(4):375-84. PubMed ID: 7199409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N''-cyano-N-4-pyridyl-N'-1,2,2-trimethylpropylguanidine, monohydrate (P 1134): a new, potent vasodilator.
    Arrigoni-Martelli E; Nielsen CK; Olsen UB; Petersen HJ
    Experientia; 1980 Apr; 36(4):445-7. PubMed ID: 7379920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pinacidil, a new vasodilator, in the treatment of patients with moderate to severe hypertension.
    Koliopoulos K; Papadoyannis DE; Karatzas NB
    Eur J Clin Pharmacol; 1984; 27(3):287-9. PubMed ID: 6510455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pinacidil, a new vasodilator, in the treatment of mild to moderate essential hypertension.
    D'Arcy V; Laher M; McCoy D; Sullivan P; Walsh CH; Hickey MP
    Eur J Clin Pharmacol; 1985; 28(3):347-9. PubMed ID: 4007040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: a new vasodilator.
    Breen EG; Mulhall D; Keogh JA
    Eur J Clin Pharmacol; 1985; 28(4):381-6. PubMed ID: 4029244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.
    Ward JW; McBurney A; Farrow PR; Sharp P
    Eur J Clin Pharmacol; 1984; 26(5):603-8. PubMed ID: 6468476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasodilator monotherapy in the treatment of hypertension: comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin.
    Goldberg MR; Sushak CS; Rockhold FW; Thompson WL
    Clin Pharmacol Ther; 1988 Jul; 44(1):78-92. PubMed ID: 3292105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension.
    Goldberg MR; Rockhold FW; Offen WW; Dornseif BE
    Clin Pharmacol Ther; 1989 Aug; 46(2):208-18. PubMed ID: 2758730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of pinacidil in hypertensive dialysis patients.
    Breen EG; Mulhall D; Keogh JA
    Eur J Clin Pharmacol; 1985; 28(4):375-80. PubMed ID: 4029243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antihypertensive effect of pinacidil versus prazosin in mild to moderate hypertensive patients seen in general practice.
    Sterndorff B; Johansen P
    Acta Med Scand; 1988; 224(4):329-36. PubMed ID: 3188983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pinacidil: history, basic pharmacology, and therapeutic implications.
    Ahnfelt-Rønne I
    J Cardiovasc Pharmacol; 1988; 12 Suppl 2():S1-4. PubMed ID: 2466172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pinacidil with and without hydrochlorothiazide. Dose-response relationships from results of a 4 x 3 factorial design study.
    Goldberg MR; Offen WW
    Drugs; 1988; 36 Suppl 7():83-92. PubMed ID: 3076140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute hemodynamic effects of pinacidil and hydralazine in essential hypertension.
    Carlsen JE; Kardel T; Lund JO; McNair A; Trap-Jensen J
    Clin Pharmacol Ther; 1985 Mar; 37(3):253-9. PubMed ID: 2857601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension.
    Goldberg MR; Rockhold FW; Thompson WL; DeSante KA
    J Clin Pharmacol; 1989 Jan; 29(1):33-40. PubMed ID: 2708546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pinacidil monotherapy for hypertension.
    Ward JW
    Br J Clin Pharmacol; 1984 Aug; 18(2):223-5. PubMed ID: 6487460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics and pharmacokinetics of pinacidil after a single dose of a new slow release tablet in healthy volunteers.
    Bareggi SR; Gambaro V; Valenti M; Benvenuti C
    Arzneimittelforschung; 1998 Jul; 48(7):730-3. PubMed ID: 9706373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology and pharmacokinetics of prizidilol in hypertensive patients.
    Chaignon M; Decourt S; Guelpa G; Rocher I; Flouvat B; Guédon J
    J Cardiovasc Pharmacol; 1983; 5(6):1068-73. PubMed ID: 6196556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.